Similarly, normal plasma cells activate NFκB in response to ligands, but their malignant counterparts, multiple myeloma cells, carry a variety of genetic mutations that stabilize NFκB-inducing kinase (NIK), which leads to constitutive activation of NFκB. The gene discussed is NFKB1; the disease is AL amyloidosis.